A to Z / Cognitive

Cerebrolysin

Also known as FPF-1070.

Best known for The brain peptide mixture used clinically outside the West

Evidence★★★☆☆

Safety dataModerately characterised

Route Injectable (intravenous, intramuscular)

United StatesNot approved

AustraliaNot registered; unapproved therapeutic good

as at 16 September 2026

What it is

Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from purified pig brain protein, rather than a single peptide. It is a registered medicine in a number of countries across Europe, Asia and the former Soviet bloc, used for stroke, traumatic brain injury and dementia, and it has a substantial human trial record.

What the full entry covers

The book carries the rest of this entry:

Where the research stands, with every claim cited
What people commonly ask, and what the research shows so far
Dosing in four labelled bands, described and not recommended
Side effects, serious risks, cautions and interactions
Questions to discuss with your doctor
How it compares with Semax, Davunetide, P21, Dihexa

Related entries

SemaxThe leading nootropic peptide · Evidence ★★☆☆☆
DavunetideThe neuroprotective peptide that reached a phase 2/3 trial, and what its results teach · Evidence ★★★☆☆
P21The neurogenesis peptide from Alzheimer's research · Evidence ★☆☆☆☆
DihexaThe Alzheimer's research peptide at an early stage of study · Evidence ★☆☆☆☆

A certificate of analysis tells you what is in a vial. The evidence rating above tells you whether the compound has been shown to work in humans. Neither answers the other's question. How to read a certificate of analysis.

This page describes what is known and not known about Cerebrolysin. It is not medical advice and not a recommendation to use it.